← Product Code [POV](/submissions/HE/subpart-f%E2%80%94automated-and-semi-automated-hematology-devices/POV) · K161493

# YO Home Sperm Test (K161493)

_Medical Electronic Systems , Ltd. · POV · Nov 8, 2016 · Hematology · SESE_

**Canonical URL:** https://fda.innolitics.com/submissions/HE/subpart-f%E2%80%94automated-and-semi-automated-hematology-devices/POV/K161493

## Device Facts

- **Applicant:** Medical Electronic Systems , Ltd.
- **Product Code:** [POV](/submissions/HE/subpart-f%E2%80%94automated-and-semi-automated-hematology-devices/POV.md)
- **Decision Date:** Nov 8, 2016
- **Decision:** SESE
- **Submission Type:** Traditional
- **Regulation:** 21 CFR 864.5220
- **Device Class:** Class 2
- **Review Panel:** Hematology
- **Attributes:** Software as a Medical Device

## Indications for Use

The YO™ Home Sperm Test is a smartphone based home test which provides a qualitative assessment of motile sperm concentration (MSC) in human semen. MSC is one aspect of a male semen examination. The YO™ Home Sperm Test does not provide a comprehensive evaluation of a male’s fertility status and is intended for over-the-counter, in vitro use only.

## Device Story

YO™ Home Sperm Test is an OTC smartphone-based system for qualitative assessment of motile sperm concentration (MSC) in human semen. The user collects a semen sample, liquefies it using provided chymotrypsin, and loads it onto a fixed coverslip slide. The slide is inserted into a proprietary 'YO™ Clip' that attaches to the user's smartphone. The YO™ software application guides the user through the process, captures a video of the sperm sample, and analyzes the video to determine if MSC is 'LOW' (<6M/mL) or 'MODERATE/NORMAL' (>=6M/mL). The device does not interpret or verify images for the user; it provides a binary result. The system is intended for home use to provide preliminary information, with recommendations to seek medical advice if results are consistently low. It benefits patients by providing an accessible, private, and rapid screening tool for one aspect of male fertility.

## Clinical Evidence

Consumer use study (n=316) compared lay-user results to trained healthcare professionals and SQA-V reference method. Overall PPA 95.3% and NPA 96.1% vs. SQA-V. Analytical performance demonstrated 93.5% PPA and 96.7% NPA vs. SQA-V across 200 samples. Limit of detection established at 3 M/mL. Interference testing showed D-norgestrel affects results.

## Technological Characteristics

Smartphone-based system comprising a proprietary optical 'Clip', fixed coverslip slides, and software application. Uses smartphone camera for video microscopy. Analyzes motile sperm concentration (MSC) via software-based video processing. Powered by smartphone. Sterilization not specified for kit components. Software is mobile-based application.

## Regulatory Identification

An automated differential cell counter is a device used to identify one or more of the formed elements of the blood. The device may also have the capability to flag, count, or classify immature or abnormal hematopoietic cells of the blood, bone marrow, or other body fluids. These devices may combine an electronic particle counting method, optical method, or a flow cytometric method utilizing monoclonal CD (cluster designation) markers. The device includes accessory CD markers.

## Special Controls

*Classification.* Class II (special controls). The special control for this device is the FDA document entitled “Class II Special Controls Guidance Document: Premarket Notifications for Automated Differential Cell Counters for Immature or Abnormal Blood Cells; Final Guidance for Industry and FDA.”

## Predicate Devices

- SpermCheck® Fertility ([K100341](/device/K100341.md))
- SQA-V sperm analyzer ([K021746](/device/K021746.md))

## Submission Summary (Full Text)

> This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com.
>
> Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/).

{0}

1

# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

A. 510(k) Number:
K161493

B. Purpose for Submission:
New device

C. Measurand:
Motile Sperm Concentration (MSC)

D. Type of Test:
Qualitative measurement of motile sperm concentration (MSC) with the use of YO software application developed specifically for Apple iPhone 5 or Samsung Galaxy 3 smartphones.

E. Applicant:
Medical Electronics Systems, Ltd.

F. Proprietary and Established Names:
YO™ Home Sperm Test

G. Regulatory Information:

1. Regulation section:
21 CFR 864.5220, Automated differential cell counter

2. Classification:
Class II

3. Product code:
POV – Semen Analysis Device

4. Panel:
Hematology (81)

H. Intended Use:

{1}

1. Intended use(s):

The YO™ Home Sperm Test is a smartphone based home test which provides a qualitative assessment of motile sperm concentration (MSC) in human semen. MSC is one aspect of a male semen examination. The YO™ Home Sperm Test does not provide a comprehensive evaluation of a male’s fertility status and is intended for over-the-counter, in vitro use only.

2. Indication(s) for use:

Same as the Intended Use

3. Special conditions for use statement(s):

Smartphone Apps for Apple iPhone 5 or Samsung Galaxy 3

4. Special instrument requirements:

Apple iPhone 5 or Samsung Galaxy 3

I. Device Description:

The YO Home Sperm Test is designed to work with home users smartphones (Apple iPhone 5 and Samsung Galaxy 3) with the downloadable YO software application and the YO Clip to measure motile sperm concentration of home users’ seminal fluid. The seminal fluid collected in the semen sample cup is liquefied with the addition of chymotrypsin with eosin. Then using the disposable plastic pipette, the liquefied seminal fluid is loaded into the coverslipped slide. The coverslipped slide containing the seminal fluid is then inserted into the YO Clip already attached to the home users’ smartphone.

The YO™ Home Sperm Test is packaged in a kit that is sufficient to run two complete tests. The kit consists of:

- Two semen collection cups
- Two vials of liquefying powder (chymotrypsin with eosin)
- Two disposable pipettes for sample aspiration
- Two fixed coverslip slides for sample testing
- One YO Clip that attaches to the smartphone and houses the fixed coverslip slide
- One plastic zip-lock Sperm Clip storage bag

J. Substantial Equivalence Information:

1. Predicate device name(s):

SpeckCheck® Fertility (Princeton BioMeditech Corporation)

SQA-V Sperm Analyzer (MES, Ltd.)

2. Predicate 510(k) number(s):

{2}

K100341

K021746

# 3. Comparison with predicate:

|  Similarities  |   |   |   |
| --- | --- | --- | --- |
|  Item | Device YOTM home test | Predicate  |   |
|   |   |  SQA-V K021746 | SpermCheck® Fertility K100341  |
|  Intended Use | YOTM is a smartphone based home tst which provides a qualitative assessment of motile sperm concentration (MSC) in human semen. MSC is a semen parameter commonly assessed in a male fertility examination. The YOTM home test does not provide a comprehensive evaluation of a male's fertility status and is intended for over-the-counter, in vitro use only. | The SQA-V is a point-of-care, electro-optical device with on-screen visualization and image freezing capabilities for semen analysis. The SQA-V provides direct and calculated measurements for: • total sperm concentration (TSC, millions/mL) • percent motility (%MOT) and % progressive motility (%PMOT) • % normal morphology (%MORPH) • motile sperm concentration (MSC, millions/mL) and progressive MSC (PMSC) • functional sperm concentration (FSC, millions/mL) | SpermCheck® Fertility is a qualitative test that detects sperm concentration at or above 20,000,000 sperm/mL. The test is intended for use as an aid in the determination of a man's fertility status. For in vitro, over the counter home use.  |
|  Sample Type | Male seminal fluid | Male seminal fluid | Male seminal fluid  |
|  Differences  |   |   |   |
| --- | --- | --- | --- |
|  Item | Device | Predicate  |   |
|  Technology | A specimen filled slide is inserted into a “Clip” which slides over the top of the Smartphone. Software downloaded onto the phone is used to capture and analyze the video of the motile sperm. | Desk-top unit consists of a light source, optical sensors, built-in video microscopy and an internal computer containing algorithms of semen parameters. | A one-step, immuno-chromatographic assay.  |
|  Measurement | Qualitative | Quantitative | Qualitative  |
|  Test Setting | Over-the-counter, Home use | Professional Use | Over-the-counter, Home use  |

{3}

4

K. Standard/Guidance Document Referenced (if applicable):

World Health Organization. (2010). WHO Laboratory Manual for the Examination and Processing of Human Semen, 5th Ed. Geneva: WHO Press

EP12-A2: User Protocol for Evaluation of Qualitative Test Performance; Approved Guideline – Second Edition.

L. Test Principle:

The YO™ Home Sperm Test utilizes Smartphone Apps developed for the iPhone 5 and Galaxy 3 for the qualitative measure of motile sperm concentration (MSC) in human semen samples. The test measures MSC to be in the LOW MSC RANGE or MODERATE/NORMAL MSC range based on the cut-off of 6 million per milliliter (6M/mL) motile sperm. If the MSC is &lt; 6M/mL the result is considered to be in the LOW MSC RANGE and if the MSC is ≥ 6 M/mL the result is considered as MODERATE/NORMAL MSC RANGE. The YO test system software recommends seeking follow-up with medical professional when the YO Home Sperm Test reports results in the LOW MSC RANGE.

M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

The precision study was conducted at two testing sites. Testing was performed using 67 fresh semen samples collected in-house at MES site and testing 76 fresh semen samples collected at a second site (Ruppin College). The collected semen samples were divided into three groups: positive (MSC &lt; 4 M/mL); close to cut-off (borderline, MSC 4 M/mL to 8 M/mL), and negative (MSC &gt; 8 M/mL). The three groupings were based on MSC values strictly from the YO Home Sperm Test system. The samples were tested in duplicate by four operators using two phones of each type (iPhone 5 and Galaxy 3), four lots of Clips and four lots of slides with total of 480 measurements per site. The study is presented in the table below:

|  Site 1: MES | Positive | Negative | Total | % Positive | % Negative  |
| --- | --- | --- | --- | --- | --- |
|  Positive (< 4M/mL)* | 38 | 0 | 19x2 phone types = 38 | 100 | 0  |
|  Borderline (4-8 M/mL)* | 20 | 16 | 18x2 phone types = 36 | 56 | 44  |
|  Negative (> 8 M/mL)* | 0 | 60 | 30x2 phone types = 60 | 0 | 100  |
|  Site 2: Ruppin College | Positive | Negative | Total | % Positive | % Negative  |
| --- | --- | --- | --- | --- | --- |

{4}

5

|  Positive (< 4M/mL)* | 62 | 0 | 31x2 phone types = 62 | 100 | 0  |
| --- | --- | --- | --- | --- | --- |
|  Borderline (4-8 M/mL)* | 27 | 21 | 24x2 phone types = 48 | 56 | 44  |
|  Negative (> 8 M/mL)* | 0 | 42 | 21x2 phone types = 42 | 0 | 100  |
|  Overall | Positive | Negative | Total | % Positive | % Negative  |
| --- | --- | --- | --- | --- | --- |
|  Positive (< 4M/mL)* | 100 | 0 | 50x2 phone types = 62 | 100 | 0  |
|  Borderline (4-8 M/mL)* | 47 | 37 | 42x2 phone types = 48 | 56 | 44  |
|  Negative (> 8 M/mL)* | 0 | 102 | 51x2 phone types = 42 | 0 | 100  |

*The three groupings were based on MSC values strictly from the YO test system.

b. Linearity/assay reportable range:

Not applicable

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

Real time stability study was completed for 2 months and accelerated stability study for 5 months that corresponds to one year was conducted. Real time stability testing is ongoing.

d. Detection limit:

The detection limit was conducted by assaying four MSC levels in duplicate by four operators using four phones of two types (iPhone 5 and Galaxy 3) and four Clip lots. The iPhone 5 is represented by "Phone 1 and Phone2" and Galaxy 3 by "Phone 3 and Phone 4". The results are provided in the table below:

All units MSC M/mL

|  Sample | Target | Assigned by SQA-V | YO™ Results |   |   |   | % Pos/Neg  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|   |   |   |  YO™ Phone 1 | YO™ Phone 2 | YO™ Phone 3 | YO™ Phone 4  |   |
|  1 | 0 | 0 | Low/Low | Low/Low | Low/Low | Low/Low | 100% Pos  |
|  2 | 2-3 | 2.7 | Low/Low | Low/Low | Low/Low | Low/Low | 100% Pos  |
|  3 | 5-6 | 5.6 | Low/MN | Low/Low | Low/Low | MN/MN | 62.5% Pos
37.5% Neg  |
|  4 | 8-9 | 8.1 | MN | MN | MN | MN | 100% Neg  |

Note: Low - LOW MSC RANGE; MN - MODERATE/NORMAL MSC RANGE

{5}

The data demonstrated 3 M/mL MSC as the limit of detection (2 times lower than 6 M/mL cut-off) and 0 for the limit of blank. The results for the sample with the MSC level close to the cut-off (5.6 MSC M/mL) were reported to be 62.5% for results in the LOW MSC RANGE and 37.5% for results at the NORMAL/MODERATE MSC RANGE.

e. Analytical specificity:

Interference testing was conducted with the potential contaminants listed in the below table. Each of the interfering substances were tested with three semen samples in the LOW MSC RANGE and three semen samples in the MODERATE/NORMAL MSC RANGE that were compared against neat semen samples at the LOW and MODERATE/NORMAL MSC RANGE. Results from the study show there was no interference from the listed interferents in table below except the hormone, D-norgestrel. Study results showed that D-norgestrel lowered the motile sperm concentration (MSC) and is indicated as an interfering hormone in the device labeling.

|  Contaminant | Origin | Original Concentration | Amount Added | Tested Concentration  |
| --- | --- | --- | --- | --- |
|  Vitamin B | Sigma Aldrich (Cat # V2876) | >98% | 5% | 50 mg/mL  |
|  Testosterone | Sigma Aldrich (Cat # 86500) | >99% | 5% | 50 mg/mL  |
|  Yeast | Acumedia (Cat # 7184A) | >98% | 5% | 9.8 x 10^{8} CFU/mL  |
|  E. coli | ATCC (Cat # 8739) | 10^{9} | 5% | 5 x 10^{7}/mL  |
|  RBC | Blood bank of Israel | 80% hematocrit | 5% | 6.1 x 10^{6}/mL  |
|  WBC | Blood bank of Israel | 10^{9} | 5% | 5 x 10^{7}/mL  |
|  Urine | Male | NA | 5% | 50 mg/mL  |
|  Saliva | Male | NA | 5% | 50 mg/mL  |
|  Agglutination | Achieved by heating samples | NA | NA | NA  |
|  D-norgestrel | Sigma Aldrich (Cat # N2260) | >99% | 5% | 50 mg/mL  |
|  B-estradiol | Sigma Aldrich (Cat # E8875) | >99% | 5% | 50 mg/mL  |

f. Assay cut-off:

The MSC assay cut-off was assessed using 100 fresh clinical semen samples consisting of MSC values approximately 50/50 above and below the 6M/mL MSC cut-off. These samples included 10% of contrived samples to supplement samples close to the cut-off. The study was conducted with two smartphone types (one iPhone 5 and one Galaxy 3) compared to the predicate device, SQA-V using four Clip lots and four slide lots of YO Home Sperm Test kit. The testing was completed in parallel within two minutes of each other on the SQA-V and YO™ to reduce the impact on the sampling time. A summary of the MSC cut-off study results are

{6}

presented in the below tables:

iPhone

|  Candidate Method | Comparative Method  |   |   |
| --- | --- | --- | --- |
|   |  Positive | Negative | Total  |
|  Positive | 51 | 1 | 52  |
|  Negative | 3 | 45 | 48  |
|  Total | 54 | 46 | 100  |

$\% \mathrm{PPA} = 100 \times a / (a + c) = 94.4\%$  PASS

$\% \mathrm{NPA} = 100 \times d / (b + d) = 97.8\%$  PASS

Galaxy

|  Candidate Method | Comparative Method  |   |   |
| --- | --- | --- | --- |
|   |  Positive | Negative | Total  |
|  Positive | 50 | 2 | 52  |
|  Negative | 4 | 44 | 48  |
|  Total | 54 | 46 | 100  |

$\% \mathrm{PPA} = 100 \times a / (a + c) = 92.6\%$  PASS

$\% \mathrm{NPA} = 100 \times d / (b + d) = 95.7\%$  PASS

Combination of both Phones

|  Candidate Method | Comparative Method  |   |   |
| --- | --- | --- | --- |
|   |  Positive | Negative | Total  |
|  Positive | 101 | 3 | 104  |
|  Negative | 7 | 89 | 96  |
|  Total | 108 | 92 | 200  |

$\% \mathrm{PPA} = 100 \times a / (a + c) = 93.5\%$  PASS

$\% \mathrm{NPA} = 100 \times d / (b + d) = 96.7\%$  PASS

2. Comparison studies:

a. Method comparison with predicate device:

See Consumer Use Study (3.c. below)

b. Matrix comparison:

Not applicable

3. Clinical studies:

a. Clinical Sensitivity:

Not applicable

b. Clinical specificity:

Not applicable

c. Other clinical supportive data (when a. and b. are not applicable):

Consumer Use Study:

Medical Electronic Systems (MES) conducted a consumer use study to evaluate the YO™ Home Sperm Test system in the hands of the intended home users. The study

{7}

was performed at three clinical sites, one in Israel and two in the U.S. The study enrolled and tested a total of 316 semen samples collected from: male subjects with no known fertility issues, a partner in a couple having difficulty conceiving, diagnosed with male factor infertility, and post-vasectomy patients or post-vasectomy reversal patients. After the test subject collected the semen samples, either the subject and/or the tester analyzed the collected sample with the YO™ Home Sperm Test kit using only the instructions provided in the kit. A separate study of YO™ Home tests using the same ejaculate, phone type and lot of YO™ test materials were tested by a trained health care professional (HCP) and by two SQA-V systems. This study design was utilized to compare YO™ results obtained by:

- Home users versus a trained healthcare professional
- Home users versus a predicate/reference method, SQA-V
- Trained healthcare professional versus a predicate/reference method, SQA-V

The results from the study are presented in percent positive agreement (PPA) and negative percent agreement (NPA) for LOW MSC RANGE (MSC &lt; 6M/mL) and MODERATE/NORMAL MSC RANGE (MSC ≥ 6M/mL). The overall results from all three sites combined are shown in the tables below:

YO™ clinical validation (Overall at 3 sites)

|  AGREEMENT: A vs. B  |   |   |   |
| --- | --- | --- | --- |
|  YO™ by Lay User (A) | YO™ by Trained User (B)  |   |   |
|   |  Positive | Negative | Total  |
|  Positive | 87 | 3 | 90  |
|  Negative | 3 | 223 | 226  |
|  Total | 90 | 226 | 316  |
|  % PPA = 100 x a/(a+c) |   | 96.7% | PASS  |
|  % NPA = 100 x d/(b+d) |   | 98.7% | PASS  |
|  AGREEMENT: A vs. C  |   |   |   |
| --- | --- | --- | --- |
|  YO™ by Lay User (A) | SQA-V (C)  |   |   |
|   |  Positive | Negative | Total  |
|  Positive | 81 | 9 | 90  |
|  Negative | 4 | 222 | 226  |
|  Total | 85 | 231 | 316  |
|  % PPA = 100 x a/(a+c) | 95.3% | PASS |   |
|  % NPA = 100 x d/(b+d) | 96.1% | PASS |   |
|  AGREEMENT: B vs. C  |   |   |   |
| --- | --- | --- | --- |
|  YO™ by Trained User (B) | SQA-V (C)  |   |   |
|   |  Positive | Negative | Total  |
|  Positive | 83 | 7 | 90  |
|  Negative | 2 | 224 | 226  |
|  Total | 85 | 231 | 316  |
|  % PPA = 100 x a/(a+c) | 97.6% |   | PASS  |
|  % NPA = 100 x d/(b+d) | 97.0% |   | PASS  |

The table below is provided to show the PPA and NPA by phone type between home users and the reference method, SQA-V.

{8}

Phone Type – Galaxy

|   |   | SQA-V  |   |   |
| --- | --- | --- | --- | --- |
|  Galaxy S |  | Low | M/N | Total  |
|   |  Low | 33 | 6 | 39  |
|   |  M/N | 1 | 96 | 97  |
|   | Total | 34 | 102 | 136  |
|  PPA = 33/34 = 97.1% |   |   | 95% CI: (84.7%; 99.9%)  |   |
|  NPA = 96/102 = 94.1% |   |   | 95% CI: (87.6%; 97.8%)  |   |

Phone Type = iPhone

|   |   | SQA-V  |   |   |
| --- | --- | --- | --- | --- |
|  iPhone S |  | Low | M/N | Total  |
|   |  Low | 48 | 3 | 51  |
|   |  M/N | 3 | 126 | 129  |
|   | Total | 51 | 129 | 180  |
|  PPA = 48/51 = 94.1% |   |   | 95% CI: (83.8%; 98.8%)  |   |
|  NPA = 126/129 = 97.7% |   |   | 95% CI: (93.4%; 99.5%)  |   |

Lay users who participated in the consumer user clinical study were asked to provide their opinion of the test and its labeling. This was accomplished via a questionnaire. The questions posed to the 316 participants are provided in the table below along with the results.

{9}

All Site Data, n = 316

|  Question # 1: Were the directions and pictures in the YO™ TEST PROCEDURE  |   |   |
| --- | --- | --- |
|  # | QUESTION | RESPONSE %  |
|  1 | Very clear and easy to follow | 81.70  |
|  2 | Somewhat clear and fairly easy to follow | 14.71  |
|  3 | Neutral | 1.96  |
|  4 | Some unclear, but could be followed | 1.31  |
|  5 | Unclear and difficult to follow | 0.33  |
|  Question # 2: Were the instructions for SAMPLE PREPARATION  |   |   |
| --- | --- | --- |
|  # | QUESTION | RESPONSE %  |
|  1 | Very clear and easy to follow | 84.97  |
|  2 | Somewhat clear and fairly easy to follow | 11.76  |
|  3 | Neutral | 1.96  |
|  4 | Some unclear, but could be followed | 1.31  |
|  5 | Unclear and difficult to follow | 0.00  |
|  Question # 3: Were the instructions for ATTACHING THE YO SPERM CLIP TO THE PHONE  |   |   |
| --- | --- | --- |
|  # | QUESTION | RESPONSE %  |
|  1 | Very clear and easy to follow | 90.85  |
|  2 | Somewhat clear and fairly easy to follow | 5.88  |
|  3 | Neutral | 2.94  |
|  4 | Some unclear, but could be followed | 0.33  |
|  5 | Unclear and difficult to follow | 0.00  |
|  Question # 4: Were the instructions for FILLING THE YO SLIDE WITH SAMPLE  |   |   |
| --- | --- | --- |
|  # | ANSWER | RESPONSE %  |
|  1 | Very clear and easy to follow | 66.89  |
|  2 | Somewhat clear and fairly easy to follow | 22.95  |
|  3 | Neutral | 6.23  |
|  4 | Some unclear, but could be followed | 3.93  |
|  5 | Unclear and difficult to follow | 0.00  |

{10}

11

|  Question # 5: Were the YO ANIMATIONS AND VIDEOS  |   |   |
| --- | --- | --- |
|  # | ANSWER | RESPONSE %  |
|  1 | Very clear and easy to follow | 89.18  |
|  2 | Somewhat clear and fairly easy to follow | 8.52  |
|  3 | Neutral | 0.66  |
|  4 | Some unclear, but could be followed | 1.31  |
|  5 | Unclear and difficult to follow | 0.33  |

4. Clinical cut-off:
Not applicable

5. Expected values/Reference range:
Not applicable

N. Instrument Name:

The YO Clip, YO slide, and the downloadable software application for smartphones, (iPhone 5 and Galaxy 3)

O. System Descriptions:

1. Modes of Operation:

Does the applicant's device contain the ability to transmit data to a computer, webserver, or mobile device?

Yes ☐ X _______ or No ☐

Does the applicant's device transmit data to a computer, webserver, or mobile device using wireless transmission?

Yes ☐ X _______ or No ☐

2. Software:

FDA has reviewed applicant's Hazard Analysis and software development processes for this line of product types:

Yes ☐ X _______ or No ☐

3. Specimen Identification:

{11}

Not available

4. Specimen Sampling and Handling:

The home users are to collect their semen samples in the collection cup provided in the YO™ Home Sperm Test kit. After collecting the sample, the liquefying powder that contains chymotrypsin with eosin is added into the cup. Then the sample containing the liquefying reagent is mixed with using gentle circular rotation for 10–15 seconds. After mixing, the sample is to rest for 12 minutes before running the test. It is recommended that users allow 2 to 7 days without ejaculating before collecting their semen sample. The sample can sit for up to one hour. Condoms and lubricants should not be used when collecting a semen sample. Proctective power free non-latex gloves are recommended for anyone other than the subject testing his own specimen. Hands should be washed with soap and water before and after handling the semen sample or any component of the test kit.

5. Calibration:

The calibration curve was established by assaying 152 semen samples using four smartphones (two of each type, iPhone 5 and Galaxy 3) and two SQA-V reference systems.

6. Quality Control:

The YO system is equipped with a built-in software electronic check to detect misalignment of the clip and slide. The built-in electronic check is also able to detect that an empty slide not filled with liquefied seminal fluid.

P. Other Supportive Instrument Performance Characteristics Data Not Covered In The "Performance Characteristics" Section above:

Disinfection study: MES Ltd., selected the EPA registered (Registration # 70627-60) Oxivir TB wipes with 0.5% hydrogen peroxide manufactured by Diversey, Inc as the disinfectant of choice for the YO Home Sperm Test system. The disinfection study was conducted at the Accuratus Lab Services in Eagan, MN. The reports from this disinfection study utilizing Duck Hepatitis B Virus as a Surrogate Virus for Human Hepatitis B Virus were provided in this 510(k) submission.

The study concluded Oxivir TB wipes (Lot 15107VX01), a ready to use pre-saturated towelette demonstrated complete inactivation of duck Hepatitis B virus following a one minute exposure time at room temperature (21.0°C) under the conditions of the investigation and in presence of a 5% fetal bovine serum organic soil for all replicates (three lots) of the coupon material surfaces of: iPhone 5 (front, back and button), Galaxy 3 (front, back, and button) and YO™ Clip.

12

{12}

Disinfection Robustness Study: To assess robustness from cleaning and disinfection with Oxivir TB wipes, a simulated cleaning and disinfecting protocol as would be utilized by home users was conducted to observe signs of thin silver streaks, cracking, swelling, dissolving, softening or brittleness of the phone case, display and buttons on the smartphone and YO™ Clip. The study was conducted on each of the smartphone types (iPhone 5 and Galaxy 3) and YO Clip by disinfecting 20 times using the recommended disinfecting towelettes (Oxivir Wipes) during the process of testing 20 semen samples. The study tested 10 “LOW” and 10 “Moderate/Normal” MSC samples compared to the reference method, SQA-V. The study produced ≥ 90% PPA and ≥ 90% NPA between YO™ Home Test kit and SQA-V for the disinfection and cleaning protocol and 100% material compatibility for the robustness study with the Oxivir TB wipes.

Q. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

R. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.

13

---

**Source:** [https://fda.innolitics.com/submissions/HE/subpart-f%E2%80%94automated-and-semi-automated-hematology-devices/POV/K161493](https://fda.innolitics.com/submissions/HE/subpart-f%E2%80%94automated-and-semi-automated-hematology-devices/POV/K161493)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com